On November 21, 2024, Humacyte, Inc. announced the publication of clinical results in JAMA Surgery, an American Medical Association peer-reviewed journal. The publication detailed the efficacy and safety of the acellular tissue engineered vessel (ATEV) in repairing extremity civilian and military injuries.
The studies, V005 and V017, demonstrated that the ATEV provided benefits in terms of patency, limb salvage, and infection resistance compared to synthetic graft benchmarks. A meta-analysis combining both trials showed a 30-day secondary patency rate of 91.5% for ATEV patients, compared to 78.9% historically reported for synthetic grafts.
Furthermore, the ATEV showed an amputation rate of 4.5% versus 24.3% for synthetic grafts, and an infection rate of 0.9% versus 8.4% for synthetic grafts. These results indicate superior outcomes for the ATEV in treating acute vascular injuries of the extremities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.